NEW YORK (GenomeWeb) – Cancer Genetics today reported a 17 percent year-over-year decrease in its second quarter revenues resulting from a drop in test volumes related to its clinical trials business.

For the three months ended June 30, the Rutherford, NJ-based cancer diagnostics firm said that revenues contracted to $1.5 million from $1.8 million in the year-ago period, missing the consensus Wall Street estimate of $2.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.